西门子医疗发布新一代全自动生化免疫分析系统Atellica(R)解决方案

2019-03-08 不详 美通社

今日,中国医学装备协会检验医学分会一带一路检验装备学组与西门子医疗携手举办“一带一路,中欧新检验实践高峰论坛 -- 精益管理, 走向临床”,就精益化管理落地、数字化、新检验标志物的临床意义等一系列热点话题进行了深入探讨。论坛上,西门子医疗发布新一代全自动生化免疫分析系统Atellica®,通过高自动化程度与快速准确的检测能力促进实验室检验能力的全面提升。在论坛的尾声,新版《临床实验诊断学

今日,中国医学装备协会检验医学分会一带一路检验装备学组与西门子医疗携手举办“一带一路,中欧新检验实践高峰论坛 -- 精益管理, 走向临床”,就精益化管理落地、数字化、新检验标志物的临床意义等一系列热点话题进行了深入探讨。论坛上,西门子医疗发布新一代全自动生化免疫分析系统Atellica®,通过高自动化程度与快速准确的检测能力促进实验室检验能力的全面提升。在论坛的尾声,新版《临床实验诊断学》中文版也与在场的各位来宾见面。这一具有行业标杆意义的专著与Atellica®同期发布,体现了西门子医疗对行业人才可持续发展的关注与支持和助力医疗机构提升价值的实践,更彰显了公司致力推动医疗精准化、诊疗模式转化、患者体验提升以及数字化医疗的决心。

免疫分析系统Atellica解决方案" align="middle" id="prnejpg6917left" alt="西门子医疗发布新一代全自动生化免疫分析系统Atellica解决方案" src="https://photos.prnasia.com/prnvar/20190308/2397820-1-a" border="0" imagelabel="General">
西门子医疗发布新一代全自动生化免疫分析系统Atellica解决方案

今日,中国医学装备协会检验医学分会一带一路检验装备学组与西门子医疗携手举办“一带一路,中欧新检验实践高峰论坛 -- 精益管理, 走向临床”。论坛上,西门子医疗发布新一代全自动生化免疫分析系统Atellica®解决方案。

Atellica®解决方案是西门子医疗十年磨一剑,隆重推出的新一代全自动生化免疫分析系统,具有高自动化程度以及快速准确的检测能力,可从掌控力、便捷性、更佳结果方面为医疗服务提供者提升价值。Atellica®解决方案的磁动传输Magline技术, 是一种创新的样本管理方式,可以双向运送。快速的磁动传输,多维视觉检视系统,智能化样本路径管理以及自动质控和校准功能,使得临床实验室独立管理每一个样本,无论是平诊还是急诊,为临床提供快速、准确的报告。其智能样本管理,减少了实验室手工操作步骤,降低检测成本。同系列的试剂和耗材统一,方便临床实验室的库存管理和报告结果的一致性;而它的便捷性则体现于灵活的扩展性设计 -- 既可独立工作也可连接Aptio 流水线,提高实验室工作流程的便捷性,从而满足实验室发展的各种需求;此外,高通量的检测仪器(免疫分析仪最高通量440测试/小时)、丰富的检测菜单、成熟的检测技术,可以提供快速、稳定、准确的检测结果,从而全面提升实验室的检验能力。

诊断学》中文版发布仪式" align="middle" id="prnejpgbdb6left" alt="全新《临床实验诊断学》中文版发布仪式" src="https://photos.prnasia.com/prnvar/20190308/2397820-1-b" border="0" imagelabel="General">
全新《临床实验诊断学》中文版发布仪式

此次论坛上发布的新版《临床实验诊断学》收录了近几年来实验室检验各个领域的新成果,旨在加强业内沟通,让临床医师更有效地理解检验结果,促进临床诊断的高效与精准化。这也与西门子医疗多年来致力提升实验室自动化水平、辅助临床医生制定个体化的治疗决策、提升患者体验、节约医疗成本的初衷不谋而合。西门子医疗大中华区副总裁、诊断系统负责人郭奕明女士表示:“近年来,检验医学的发展迅猛,却也面临全新挑战。针对时代赋予我们的新命题,西门子医疗携手中国医学装备协会检验医学分会一带一路检验装备学组,联合搭建同业交流的平台。我们坚信,今日的讨论将为检验医学的未来发展铺平道路。未来,我们也将持续为实验室量身定制标准化、自动化的精益管理解决方案,并提供高医学价值的创新型产品。”

西门子医疗新一代全自动生化免疫分析系统Atellica解决方案
西门子医疗新一代全自动生化免疫分析系统Atellica解决方案

近年来,西门子医疗在实验室诊断领域不断投入。2018年10月19日,西门子医疗宣布投资人民币30亿元新建实验室诊断工厂,并在上海举行了奠基典礼。该工厂落成后,上海将成为西门子医疗影像诊断与实验室诊断产品生产的综合性创新基地。新的实验室诊断工厂将进一步拓展西门子医疗全球生产制造版图,并将通过收集市场洞察与提供更多本地化产品和解决方案,更好地满足中国医疗服务提供者不断变化的需求。

西门子医疗大中华区总裁王皓先生表示:“西门子医疗始终以‘助力医疗服务提供者提升价值’为己任,相信此次全新一代Atellica®解决方案的推出,能更好地满足实验室日益增长的检测量与患者的医疗需求,从而促进医疗资源的合理分配,为患者带来更高效、更高质的医疗服务,为‘健康中国2030’规划的落地实施做出贡献。”

关于西门子医疗

西门子医疗致力于通过支持全球医疗服务提供者在各自领域推进精准医疗、转化诊疗模式、改善患者体验以及实现数字化医疗,以全方位助力其提升价值。作为医疗科技领域的领导者,西门子医疗始终致力于产品组合的创新,并着力完善核心业务 -- 影像诊断、临床诊疗与实验室诊断、分子医学的配套服务业务系统。此外,西门子医疗更积极推进其在数字健康服务与医疗企业管理方案领域的业务延伸。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1988012, encodeId=f3341988012ce, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Sun Jul 07 22:25:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928160, encodeId=70421928160eb, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Apr 17 21:25:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058257, encodeId=2cab205825e20, content=<a href='/topic/show?id=d4cf293132' target=_blank style='color:#2F92EE;'>#Atellica#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2931, encryptionId=d4cf293132, topicName=Atellica)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Sep 14 16:25:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666911, encodeId=9ee116669110d, content=<a href='/topic/show?id=f2b0905506a' target=_blank style='color:#2F92EE;'>#西门子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90550, encryptionId=f2b0905506a, topicName=西门子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e226073684, createdName=bshuang, createdTime=Fri Dec 06 08:25:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604668, encodeId=6f2d160466841, content=<a href='/topic/show?id=d3689055158' target=_blank style='color:#2F92EE;'>#西门子医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90551, encryptionId=d3689055158, topicName=西门子医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e34419265734, createdName=1249842em15(暂无昵称), createdTime=Sun Mar 10 13:25:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1988012, encodeId=f3341988012ce, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Sun Jul 07 22:25:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928160, encodeId=70421928160eb, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Apr 17 21:25:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058257, encodeId=2cab205825e20, content=<a href='/topic/show?id=d4cf293132' target=_blank style='color:#2F92EE;'>#Atellica#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2931, encryptionId=d4cf293132, topicName=Atellica)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Sep 14 16:25:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666911, encodeId=9ee116669110d, content=<a href='/topic/show?id=f2b0905506a' target=_blank style='color:#2F92EE;'>#西门子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90550, encryptionId=f2b0905506a, topicName=西门子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e226073684, createdName=bshuang, createdTime=Fri Dec 06 08:25:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604668, encodeId=6f2d160466841, content=<a href='/topic/show?id=d3689055158' target=_blank style='color:#2F92EE;'>#西门子医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90551, encryptionId=d3689055158, topicName=西门子医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e34419265734, createdName=1249842em15(暂无昵称), createdTime=Sun Mar 10 13:25:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1988012, encodeId=f3341988012ce, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Sun Jul 07 22:25:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928160, encodeId=70421928160eb, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Apr 17 21:25:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058257, encodeId=2cab205825e20, content=<a href='/topic/show?id=d4cf293132' target=_blank style='color:#2F92EE;'>#Atellica#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2931, encryptionId=d4cf293132, topicName=Atellica)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Sep 14 16:25:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666911, encodeId=9ee116669110d, content=<a href='/topic/show?id=f2b0905506a' target=_blank style='color:#2F92EE;'>#西门子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90550, encryptionId=f2b0905506a, topicName=西门子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e226073684, createdName=bshuang, createdTime=Fri Dec 06 08:25:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604668, encodeId=6f2d160466841, content=<a href='/topic/show?id=d3689055158' target=_blank style='color:#2F92EE;'>#西门子医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90551, encryptionId=d3689055158, topicName=西门子医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e34419265734, createdName=1249842em15(暂无昵称), createdTime=Sun Mar 10 13:25:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1988012, encodeId=f3341988012ce, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Sun Jul 07 22:25:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928160, encodeId=70421928160eb, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Apr 17 21:25:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058257, encodeId=2cab205825e20, content=<a href='/topic/show?id=d4cf293132' target=_blank style='color:#2F92EE;'>#Atellica#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2931, encryptionId=d4cf293132, topicName=Atellica)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Sep 14 16:25:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666911, encodeId=9ee116669110d, content=<a href='/topic/show?id=f2b0905506a' target=_blank style='color:#2F92EE;'>#西门子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90550, encryptionId=f2b0905506a, topicName=西门子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e226073684, createdName=bshuang, createdTime=Fri Dec 06 08:25:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604668, encodeId=6f2d160466841, content=<a href='/topic/show?id=d3689055158' target=_blank style='color:#2F92EE;'>#西门子医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90551, encryptionId=d3689055158, topicName=西门子医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e34419265734, createdName=1249842em15(暂无昵称), createdTime=Sun Mar 10 13:25:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]
    2019-12-06 bshuang
  5. [GetPortalCommentsPageByObjectIdResponse(id=1988012, encodeId=f3341988012ce, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Sun Jul 07 22:25:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928160, encodeId=70421928160eb, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Apr 17 21:25:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058257, encodeId=2cab205825e20, content=<a href='/topic/show?id=d4cf293132' target=_blank style='color:#2F92EE;'>#Atellica#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2931, encryptionId=d4cf293132, topicName=Atellica)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Sep 14 16:25:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666911, encodeId=9ee116669110d, content=<a href='/topic/show?id=f2b0905506a' target=_blank style='color:#2F92EE;'>#西门子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90550, encryptionId=f2b0905506a, topicName=西门子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e226073684, createdName=bshuang, createdTime=Fri Dec 06 08:25:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604668, encodeId=6f2d160466841, content=<a href='/topic/show?id=d3689055158' target=_blank style='color:#2F92EE;'>#西门子医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90551, encryptionId=d3689055158, topicName=西门子医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e34419265734, createdName=1249842em15(暂无昵称), createdTime=Sun Mar 10 13:25:00 CST 2019, time=2019-03-10, status=1, ipAttribution=)]

相关资讯

2019年2月20日,由中华国际医学交流基金会与西门子医疗联合举办的2019智能医疗高峰论坛在北京召开。超过150位来自政府、行业协会、医疗机构的领导和专家们,

2019年2月20日,由中华国际医学交流基金会与西门子医疗联合举办的2019智能医疗高峰论坛在北京召开。超过150位来自政府、行业协会、医疗机构的领导和专家们,以及来自阿里健康、平安好医、腾讯医疗、深睿、依图、推想、科大讯飞、柏视医疗、数坤、图码深维、雅森、筑医台、安德医智、希氏异构等医疗人工智能公司的负责人齐聚一堂,共同探讨医疗数字化在全球以及中国的发展现状与趋势,以及医疗行业在人工智能及数字化